When it comes to assessing the safety of CBD in foods, the EU appears to be lagging behind the UK. Food Standards Agency CEO Emily Miles has noted that EFSA recently reached the same conclusions as the UK’s Committee on Toxicity did two years ago: there are still evidence gaps relating to CBD as a food. This may reassure UK operators that with the FSA further along in the assessment process it will not follow EFSA in suspending CBD novel food applications - but as expert Greer Deal notes, it's too soon to say.
Europe is two years behind the UK when it comes to assessing cannabidiol’s safety, the UK Food Standards Agency’s CEO Emily Miles has suggested.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
Eleat's acquisition encompasses Clasado's Bimuno finished supplement product line and customer base, but not its Bimuno GOS proprietary galactooligosaccharide prebiotic ingredient.
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
HBW Insight catches up with PAGB CEO Michelle Riddalls to chat about the association's new five year plan. Riddalls also reflects on the successes of the last five years, including relaunching the UK Reclassification Alliance, which has published a list of Rx-to-OTC switches the government would like to see applications for. Part one of two.
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.
